Use of an Aluvia Based Highly Active Antiretroviral Therapy (HAART) Regimen in the Prevention of Mother to Child HIV Transmission (PMTCT) Antepartum, Intrapartum and Postpartum in Africa.

Trial Profile

Use of an Aluvia Based Highly Active Antiretroviral Therapy (HAART) Regimen in the Prevention of Mother to Child HIV Transmission (PMTCT) Antepartum, Intrapartum and Postpartum in Africa.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jun 2015

At a glance

  • Drugs Lamivudine/zidovudine; Lopinavir/ritonavir; Nevirapine
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms PMTCT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Mar 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top